← All trials
NCT04448392
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Oct 31, 2025
- Completion date
- Nov 30, 2025
- First posted
- Jun 25, 2020
- Last posted
- Jun 25, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.